Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
Interventions: JenaValve Trilogy Heart Valve System; Device
Lead sponsor: JenaValve Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 25 more

Conditions: Obesity, Inflammation
Interventions: high protein diet, high carbohydrate diet; Dietary Supplement
Lead sponsor: University of Tennessee; Other
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Prostate Cancer, Cardiovascular Diseases
Interventions: CV Care Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lung Cancer, Heart Disease
Interventions: Picture warning, Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma
Interventions: bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 7,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 267
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more

Conditions: Hepatitis C
Interventions: Elbasvir/grazoprevir; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rural Health, Pulmonary Disease, Heart Diseases
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 25 Years to 64 Years
Enrollment: 4,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension, Cardiovascular Disease, Metabolic Disorders
Interventions: Not listed
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cardiovascular Diseases
Interventions: Telmisartan, Combination of Telmisartan and Ramipril, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 31,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 100
States / cities: Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more

Conditions: Psoriasis, Obesity, Cardiovascular Risk, Inflammation
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 18 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Interventions: sitaxsentan (Thelin), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 48 Years to 82 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Charleston, South Carolina • Chattanooga, Tennessee

Conditions: Peripheral Arterial Disease
Interventions: Therapeutic Device; Device
Lead sponsor: Vibrato Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orange, California

Conditions: Vascular Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions: Corus CAD (ASGES); Diagnostic Test
Lead sponsor: CardioDx; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 4,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 10
States / cities: Anchorage, Alaska • Beverly Hills, California • La Jolla, California + 7 more

Conditions: Cardiovascular Diseases, Heart Diseases, Obesity
Interventions: Single behavior intervention, Multiple behavior interventions, Control Intervention unrelated to weight; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 12 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Lung Disease, Pulmonary Hypertension
Interventions: Observational Study; Diagnostic Test
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carotid Artery Disease
Interventions: Mo.Ma cerebral protection device; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Buffalo, New York • Columbus, Ohio

Conditions: Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 80
States / cities: Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 73 more

Conditions: Sedentary Lifestyle, Risk Factor, Cardiovascular
Interventions: Treadmill desk; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cardiovascular Risk Factor
Interventions: South Asian Healthy Lifestyle Initiative (SAHELI); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia
Interventions: Praluent; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 57
States / cities: Auburn, Alabama • Mobile, Alabama • Beverly Hills, California + 50 more

Conditions: Coronary Artery Disease, Heart Disease
Interventions: Perflutren Lipid Microsphere Injectable Suspension; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Search by objective public record fields.

The JenaValve ALIGN-AR Pivotal Trial

Effect of Diet Composition on Weight Change and Metabolic Parameters

CV CARE: CardioVascular Care in PC Patients

Communicating Smoking Risks Through Graphic Warning Labels

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study

Socioeconomic Status, Psychosocial Factors, and CVD Risk in Mexican-American Women

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

A Non-significant Risk Clinical Study to Assess Perfusion Changes With Application of a TUS for Patients With PAD

The Framingham Study: Examining DNA Markers and Links to Diseases

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

Behavior Change Family Counseling to Reduce Rate of Weight Gain in At-Risk Children

Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension

Proximal Protection With The Mo.Ma Device During Carotid Stenting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Assessing the Effects Of Treadmill On LPA, Sitting Time, and Cardiovascular Risk

South Asian Healthy Lifestyle Initiative (SAHELI)

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Long Term Safety Study of PRALUENT

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease